These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15197209)

  • 1. Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial.
    Butler L; Bacon M; Carey M; Zee B; Tu D; Bezjak A
    J Clin Oncol; 2004 Jun; 22(12):2461-8. PubMed ID: 15197209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study.
    Bezjak A; Tu D; Bacon M; Osoba D; Zee B; Stuart G; Roy JA; Piccart M; Eisenhauer E
    J Clin Oncol; 2004 Nov; 22(22):4595-603. PubMed ID: 15466785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
    Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
    J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer.
    Carey MS; Bacon M; Tu D; Butler L; Bezjak A; Stuart GC
    Gynecol Oncol; 2008 Jan; 108(1):100-5. PubMed ID: 17920108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial.
    Reck M; von Pawel J; Macha HN; Kaukel E; Deppermann KM; Bonnet R; Ulm K; Hessler S; Gatzemeier U
    Lung Cancer; 2006 Jul; 53(1):67-75. PubMed ID: 16713013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life in ovarian cancer patients receiving chemotherapy.
    Lakusta CM; Atkinson MJ; Robinson JW; Nation J; Taenzer PA; Campo MG
    Gynecol Oncol; 2001 Jun; 81(3):490-5. PubMed ID: 11371144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life analyses in a clinical trial of DPPE (tesmilifene) plus doxorubicin versus doxorubicin in patients with advanced or metastatic breast cancer: NCIC CTG Trial MA.19.
    Liu J; Tu D; Dancey J; Reyno L; Pritchard KI; Pater J; Seymour LK
    Breast Cancer Res Treat; 2006 Dec; 100(3):263-71. PubMed ID: 16823511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group study.
    McQuellon RP; Thaler HT; Cella D; Moore DH
    Gynecol Oncol; 2006 May; 101(2):296-304. PubMed ID: 16376417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study.
    Wenzel LB; Huang HQ; Armstrong DK; Walker JL; Cella D;
    J Clin Oncol; 2007 Feb; 25(4):437-43. PubMed ID: 17264340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study.
    Bottomley A; Gaafar R; Manegold C; Burgers S; Coens C; Legrand C; Vincent M; Giaccone G; Van Meerbeeck J; ;
    J Clin Oncol; 2006 Mar; 24(9):1435-42. PubMed ID: 16446322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study.
    Bottomley A; Biganzoli L; Cufer T; Coleman RE; Coens C; Efficace F; Calvert HA; Gamucci T; Twelves C; Fargeot P; Piccart M;
    J Clin Oncol; 2004 Jul; 22(13):2576-86. PubMed ID: 15226325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
    van Meerbeeck JP; Gaafar R; Manegold C; Van Klaveren RJ; Van Marck EA; Vincent M; Legrand C; Bottomley A; Debruyne C; Giaccone G; ;
    J Clin Oncol; 2005 Oct; 23(28):6881-9. PubMed ID: 16192580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of EORTC QLQ-C30 questionnaire in patients undergoing in-hospital chemotherapy for gastrointestinal cancer in Japan.
    Kato J; Nagahara A; Iijima K; Yoshimura M; Osada T; Yoshizawa T; Watanabe S
    J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S268-72. PubMed ID: 19120910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase III randomized study comparing paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with advanced ovarian cancer.
    Mouratidou D; Gennatas C; Michalaki V; Papadimitriou A; Andreadis CH; Sykiotis C; Tsavaris N
    Anticancer Res; 2007; 27(1B):681-5. PubMed ID: 17348460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
    Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
    J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study.
    Monk BJ; Huang HQ; Cella D; Long HJ;
    J Clin Oncol; 2005 Jul; 23(21):4617-25. PubMed ID: 15911864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial.
    Taphoorn MJ; van den Bent MJ; Mauer ME; Coens C; Delattre JY; Brandes AA; Sillevis Smitt PA; Bernsen HJ; Frénay M; Tijssen CC; Lacombe D; Allgeier A; Bottomley A;
    J Clin Oncol; 2007 Dec; 25(36):5723-30. PubMed ID: 18089866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Spriggs DR; Brady MF; Vaccarello L; Clarke-Pearson DL; Burger RA; Mannel R; Boggess JF; Lee RB; Hanly M
    J Clin Oncol; 2007 Oct; 25(28):4466-71. PubMed ID: 17906207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.
    Rosenthal SA; Bae K; Pienta KJ; Sobczak ML; Asbell SO; Rajan R; Kerlin KJ; Michalski JM; Sandler HM;
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):672-8. PubMed ID: 18990504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective assessment of quality of life in ovarian cancer patients receiving whole abdomen hyperthermia and liposomal doxorubicin.
    Hahn CA; Jones EL; Blivin JL; Sanders LL; Yu D; Dewhirst MW; Secord AA; Prosnitz LR
    Int J Hyperthermia; 2005 Jun; 21(4):349-57. PubMed ID: 16019860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.